Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.

EP: 1.Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP: 2.Real-World Impact of SUNLIGHT Outcomes in mCRC

EP: 3.Fruquintinib in mCRC: Key Insights From FRESCO-2

Now Viewing

EP: 4.Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP: 5.Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP: 6.Guiding Patients Through Third-Line mCRC Therapy Decisions

EP: 7.Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP: 8.Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP: 9.Integrating Support Services and Caregiver Roles in mCRC Care

EP: 10.mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

Video content above is prompted by the following:

How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?

Related Videos

Related Content

Advertisement

November 20th 2024

Study Highlights Key RA-ILD Risk Factors, Urges Early Screening

Brooke McCormick

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 20th 2024

Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed

Gayle Turim Dickstein

Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 19th 2024

Influenza Antiviral Treatment Underutilized Among Eligible Children, Adolescents

Brooke McCormick

Influenza antiviral treatment remains underutilized among eligible children and adolescents, particularly in outpatient settings, despite CDC recommendations.

November 19th 2024

New PsA Data Highlight Long-Term Benefits of Bimekizumab

Maggie L. Shaw

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).

Related Content

Advertisement

November 20th 2024

Study Highlights Key RA-ILD Risk Factors, Urges Early Screening

Brooke McCormick

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 20th 2024

Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed

Gayle Turim Dickstein

Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 19th 2024

Influenza Antiviral Treatment Underutilized Among Eligible Children, Adolescents

Brooke McCormick

Influenza antiviral treatment remains underutilized among eligible children and adolescents, particularly in outpatient settings, despite CDC recommendations.

November 19th 2024

New PsA Data Highlight Long-Term Benefits of Bimekizumab

Maggie L. Shaw

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).